News Breaks |
|
|
| February 5, 2013 |
| 10:00 EDT |  | ARRY | Array BioPharma now sees FY13 EPS (55c), prior view (60c)
Consensus for FY13 EPS (58c). Lowered FY13 revenue view to $60M from $62M prior guidance, consensus $63.03M. Guidance from slides for Q2 earnings conference call. |
|
|
News For ARRY From The Last 14 Days Check below for free stories on ARRY the last two weeks. |
|
|
| May 15, 2013 |
| 09:51 EDT |  | ARRY | Array BioPharma management to meet with Leerink
Meeting to be held in San Francisco on May 17 hosted by Leerink. |
|
| May 6, 2013 |
| 16:25 EDT | | ARRY | Array BioPharma reaffirms FY13 EPS (55c), consensus (54c)
 Subscribe for More Information |
|
| 16:23 EDT |  | ARRY | Array to start first company-led Phase 3 trial with MEK162
Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. |
|
| 16:20 EDT | | ARRY | Array BioPharma reports Q3 EPS (19c), consensus (15c)
Reports Q3 revenue $10M consensus $14.54M. |
|
| 16:04 EDT | | ARRY | Array BioPharma to initiate Phase 3 trial evaluating MEK162
Subscribe for More Information |
|
|
|
|
|
